Delcath Systems Inc (DCTH)

$10.78 -0.17 (-1.55%)
Market Cap 372.15M
Revenue (ttm) 85.23M
Net Income (ttm) 2.70M
EPS (ttm) N/A
PE Ratio 1,095.00
Forward PE N/A
Profit Margin 3.17%
Debt to Equity Ratio 0.00
Volume 424,700
Avg Vol 372,174
Day's Range N/A - N/A
Shares Out 34.52M
Stochastic %K 13%
Beta 0.54
Analysts Strong Sell
Price Target $21.67

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal...

Industry: Medical Devices
Sector: Healthcare
Phone: 212 489 2100
Fax: 212 489 2102
Address:
566 Queensbury Avenue, Queensbury, United States
alexpitti
alexpitti Jun. 1 at 1:49 AM
$DCTH replimune reported their data on rp2 which is their lesser known drug, but matters for us since it treats mUM among other things. they reported a pooled ORR of 33.3%. they had already reported 29.4% ORR in 5 of 17 patients. it looks to me like they added a few patients and maybe it went to 7 of 21 patients. they didn't say the exact number, but it's 1/3 obviously. this supports their goal of completing their trial, but not much else. i don't think delcath stock will react to this monday
0 · Reply
pufferfishcapital
pufferfishcapital May. 31 at 6:48 PM
$DCTH Breast trial has Cleveland Clinic, Moffitt, Ohio State, UT Southwestern, and IEO Milan. mCRC has City of Hope, Utah, Moffitt, Ochsner, UCLA, Kansas. There may be other intl sites not sure. Commercial requires a specific set of steps as prescribed in the FDA label i.e. proctoring, etc. A trial is less restrictive because the trial is done under a IND application. Ochsner has been listed in the HEPZATO referral site for quite a while and I am sure will eventually offer the procedure commercially, but I have no idea why it hasn't happened yet
0 · Reply
Jfree1121
Jfree1121 May. 30 at 11:27 AM
$DCTH if you spend a little time using any sort of AI platform, you can quickly find about 32 active centers. Throughout the country. And those are just ones that are publicly disclosed. There's probably at least half a dozen if not a dozen more that are currently leaning into it, but haven't publicly shared. Again, zoom out, the company continues to improve its financial standing and technology adoption quarter over quarter. I've been wrong about a number of stocks before, but this one I'm extremely bullish on 
1 · Reply
Value1008
Value1008 May. 30 at 12:00 AM
$DCTH - in some prior threads, Alex has mentioned the biotech (biomedical device) etf IHI as a sector comparison. IHI holds shares of large cap stocks, so doesn't currently hold any DCTH shares. But the overall sector sentiment would certainly seem to be influenced by IHI's performance. I queried Google AI on why the biomed device sector is so weak. Here was the reply: Stock values in the biomedical device (medtech) sector are being weighed down by a combination of high-valuation hangovers, supply-chain tariff pressures, and emerging fears that weight-loss drugs will reduce the long-term need for chronic disease interventions.The sector is facing several primary headwinds: The "GLP-1" Threat: The massive popularity of weight-loss drugs (like Wegovy and Zepbound) has sparked investor fear that a thinner, healthier population will require fewer cardiovascular interventions, joint replacements, and sleep apnea devices. [Continued...]
2 · Reply
Jfree1121
Jfree1121 May. 29 at 11:51 PM
$DCTH this is a long hold and will run. I know several docotors that rave about this tech and its results. Give it time people. Learn about the tech - this is a long term hold. If you're looking at it daily - just sell and move on or stfu.
1 · Reply
mar99
mar99 May. 29 at 8:04 PM
$DCTH Our typical end of day walk down. Another day of record highs in the indexes. Another day of garbage action in this dreadfully poor stock to be holding.
1 · Reply
alexpitti
alexpitti May. 29 at 6:29 PM
Someone fat fingered $DCTH no this is NOT an ai stock. Go back to your usual selling
0 · Reply
boohoooomillenials
boohoooomillenials May. 29 at 4:17 PM
$DCTH in at 10.74 with a 30k starter. Looking for 60-80% return
0 · Reply
mar99
mar99 May. 29 at 2:42 PM
$DCTH I guess today they aren’t bothering to run the stock up before the take down and figured it’s easier to just take it down. Tough place to be in this bull market. Hard to see any catalyst coming any time soon to change the story here with the stock price. S&P can go over 8,000 and we will still be struggling to see 11.
0 · Reply
alexpitti
alexpitti May. 29 at 1:30 PM
the fda is reviewing RP1 again quickly. seems like an approval is likely in the next 6 months. that will give replimune the money to keep funding the RP2 trial which competes with delcath. i think most of the enrollment will be done by year end. but an approval is still a few years away $DCTH
0 · Reply
Latest News on DCTH
Delcath Systems announces ASCO 2026 investigator initiated trials-in-progress

2026-05-26T20:05:59.000Z - 5 days ago

Delcath Systems announces ASCO 2026 investigator initiated trials-in-progress

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

May 26, 2026, 4:01 PM EDT - 5 days ago

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 15, 2026, 4:01 PM EDT - 16 days ago

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026, 8:00 AM EDT - 20 days ago

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Delcath Systems presents new data on M-PHP at ESMO

2026-05-07T14:11:04.000Z - 24 days ago

Delcath Systems presents new data on M-PHP at ESMO

Delcath Systems reports Q1 EPS (3c), consensus (9c)

2026-05-07T13:35:47.000Z - 25 days ago

Delcath Systems reports Q1 EPS (3c), consensus (9c)

Delcath Systems backs FY26 revenue view at least $100M, consensus $102.69M

2026-05-07T13:34:32.000Z - 25 days ago

Delcath Systems backs FY26 revenue view at least $100M, consensus $102.69M

Delcath Systems Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 25 days ago

Delcath Systems Earnings Call Transcript: Q1 2026

Delcath Systems Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 25 days ago

Delcath Systems Earnings release: Q1 2026

Delcath Systems Quarterly report: Q1 2026

May 7, 2026, 8:30 AM EDT - 25 days ago

Delcath Systems Quarterly report: Q1 2026

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

May 7, 2026, 8:00 AM EDT - 25 days ago

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

May 7, 2026, 7:00 AM EDT - 25 days ago

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Delcath Systems to Host First Quarter 2026 Earnings Call

Apr 23, 2026, 8:30 AM EDT - 5 weeks ago

Delcath Systems to Host First Quarter 2026 Earnings Call

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

Apr 6, 2026, 8:30 AM EDT - 2 months ago

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

Delcath Systems management to meet with Craig Hallum

2026-04-02T14:44:15.000Z - 2 months ago

Delcath Systems management to meet with Craig Hallum

Delcath Systems Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Delcath Systems Proxy statement: Proxy filing

Delcath Systems Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 2 months ago

Delcath Systems Proxy statement: Proxy filing

Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting

Apr 1, 2026, 8:30 AM EDT - 2 months ago

Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting

Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology

2026-03-03T13:43:26.000Z - 3 months ago

Delcath Systems publishes results from CHOPIN trial in The Lancet Oncology

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

Mar 3, 2026, 8:00 AM EST - 3 months ago

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

Delcath Systems price target lowered to $27 from $29 at Clear Street

2026-02-26T18:26:15.000Z - 3 months ago

Delcath Systems price target lowered to $27 from $29 at Clear Street

Delcath Systems reports Q4 EPS (5c), consensus (3c)

2026-02-26T13:33:50.000Z - 3 months ago

Delcath Systems reports Q4 EPS (5c), consensus (3c)

Delcath Systems sees FY26 revenue at least $100M, consensus $110.56M

2026-02-26T13:33:07.000Z - 3 months ago

Delcath Systems sees FY26 revenue at least $100M, consensus $110.56M

Delcath Systems Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 3 months ago

Delcath Systems Earnings Call Transcript: Q4 2025

Delcath Systems Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 3 months ago

Delcath Systems Annual report: Q4 2025

Delcath Systems Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 3 months ago

Delcath Systems Earnings release: Q4 2025

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

Feb 26, 2026, 8:00 AM EST - 3 months ago

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

Feb 12, 2026, 8:00 AM EST - 3 months ago

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 27, 2026, 8:05 AM EST - 4 months ago

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Delcath Systems price target raised to $29 from $28 at Clear Street

2026-01-09T15:30:16.000Z - 5 months ago

Delcath Systems price target raised to $29 from $28 at Clear Street

Delcath Systems reports preliminary Q4 revenue $20.7M, consensus $19.99M

2026-01-09T13:15:29.000Z - 5 months ago

Delcath Systems reports preliminary Q4 revenue $20.7M, consensus $19.99M

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Jan 9, 2026, 8:05 AM EST - 5 months ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Delcath Systems publishes results from subgroup analyses of FOCUS study

2025-12-31T13:15:08.000Z - 5 months ago

Delcath Systems publishes results from subgroup analyses of FOCUS study

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

Dec 31, 2025, 8:00 AM EST - 5 months ago

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

Delcath Systems announces publication of CHEMOSAT study

2025-12-03T21:05:29.000Z - 6 months ago

Delcath Systems announces publication of CHEMOSAT study

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Dec 3, 2025, 4:01 PM EST - 6 months ago

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Delcath Systems authorizes $25M buyback program

2025-11-20T21:05:49.000Z - 6 months ago

Delcath Systems authorizes $25M buyback program

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

Nov 20, 2025, 4:01 PM EST - 6 months ago

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

Delcath Systems publishes review of Hepzato Kit

2025-11-18T14:38:40.000Z - 6 months ago

Delcath Systems publishes review of Hepzato Kit

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

Nov 18, 2025, 8:00 AM EST - 6 months ago

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

Delcath announces publication supporting early use of liver-directed therapy

2025-11-13T14:21:28.000Z - 7 months ago

Delcath announces publication supporting early use of liver-directed therapy

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

Nov 13, 2025, 8:30 AM EST - 7 months ago

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

Delcath Systems to Participate in Upcoming Investor Conferences

Nov 6, 2025, 4:01 PM EST - 7 months ago

Delcath Systems to Participate in Upcoming Investor Conferences

Delcath Systems Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 7 months ago

Delcath Systems Earnings Call Transcript: Q3 2025

Delcath Systems Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 7 months ago

Delcath Systems Quarterly report: Q3 2025

Delcath Systems Earnings release: Q3 2025

Nov 4, 2025, 8:30 AM EST - 7 months ago

Delcath Systems Earnings release: Q3 2025

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

Nov 4, 2025, 8:00 AM EST - 7 months ago

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

Delcath Systems price target lowered to $20 from $24 at Craig-Hallum

2025-10-21T13:05:37.000Z - 7 months ago

Delcath Systems price target lowered to $20 from $24 at Craig-Hallum

Delcath Systems to Host Third Quarter 2025 Earnings Call

Oct 21, 2025, 8:30 AM EDT - 7 months ago

Delcath Systems to Host Third Quarter 2025 Earnings Call

Clear Street ups Delcath target, sees opportunity on selloff

2025-10-20T16:00:49.000Z - 7 months ago

Clear Street ups Delcath target, sees opportunity on selloff

Delcath Systems Transcript: Study Result

Oct 20, 2025, 8:45 AM EDT - 8 months ago

Delcath Systems Transcript: Study Result

Delcath Systems Press release: Study Result

Oct 20, 2025, 8:45 AM EDT - 8 months ago

Delcath Systems Press release: Study Result

Delcath Systems Slides: Corporate Presentation

Oct 20, 2025, 7:00 AM EDT - 8 months ago

Delcath Systems Slides: Corporate Presentation

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Oct 18, 2025, 4:15 PM EDT - 8 months ago

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Oct 18, 2025, 4:13 PM EDT - 8 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

Sep 22, 2025, 4:01 PM EDT - 8 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

Delcath Systems Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 11:00 AM EDT - 9 months ago

Delcath Systems Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Aug 19, 2025, 8:30 AM EDT - 10 months ago

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Delcath Systems Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 10 months ago

Delcath Systems Earnings Call Transcript: Q2 2025

Delcath Systems Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 10 months ago

Delcath Systems Quarterly report: Q2 2025

Delcath Systems Earnings release: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 10 months ago

Delcath Systems Earnings release: Q2 2025

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

Aug 6, 2025, 8:00 AM EDT - 10 months ago

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 29, 2025, 4:01 PM EDT - 10 months ago

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

Delcath Systems to Host Second Quarter 2025 Earnings Call

Jul 23, 2025, 4:01 PM EDT - 11 months ago

Delcath Systems to Host Second Quarter 2025 Earnings Call

Delcath Systems Slides: Investor Presentation

May 22, 2025, 10:00 AM EDT - 1 year ago

Delcath Systems Slides: Investor Presentation

Delcath Systems Issues Full Year 2025 Guidance

May 22, 2025, 7:00 AM EDT - 1 year ago

Delcath Systems Issues Full Year 2025 Guidance

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 15, 2025, 4:30 PM EDT - 1 year ago

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025, 5:30 PM EDT - 1 year ago

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Earnings Call Transcript: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Earnings Call Transcript: Q1 2025

Delcath Systems Quarterly report: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Quarterly report: Q1 2025

Delcath Systems Earnings release: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Earnings release: Q1 2025

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

May 8, 2025, 7:30 AM EDT - 1 year ago

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Apr 28, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Delcath Systems to Host First Quarter 2025 Earnings Call

Apr 24, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Host First Quarter 2025 Earnings Call

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Apr 9, 2025, 5:00 PM EDT - 1 year ago

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Delcath Systems Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Delcath Systems Proxy statement: Proxy Filing

Delcath Systems Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Delcath Systems Proxy statement: Proxy Filing

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 24, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 14, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Earnings Call Transcript: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Earnings Call Transcript: Q4 2024

Delcath Systems Annual report: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Annual report: Q4 2024

Delcath Systems Earnings release: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Earnings release: Q4 2024

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Mar 6, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Feb 20, 2025, 8:30 AM EST - 1 year ago

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Feb 14, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Biotech walks a 'tightrope' amid unclear funding, regulations

Jan 30, 2025, 7:06 PM EST - 1 year ago

Biotech walks a 'tightrope' amid unclear funding, regulations

ELVN IBB

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 28, 2025, 4:01 PM EST - 1 year ago

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Jan 13, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 3, 2025, 4:01 PM EST - 1 year ago

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Dec 30, 2024, 8:00 AM EST - 1 year ago

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Dec 2, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Delcath Systems Earnings Call Transcript: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Earnings Call Transcript: Q3 2024

Delcath Systems Quarterly report: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Quarterly report: Q3 2024

Delcath Systems Earnings release: Q3 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Earnings release: Q3 2024

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

Nov 8, 2024, 8:00 AM EST - 1 year ago

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

Delcath Systems to Host Third Quarter 2024 Earnings Call

Oct 25, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems to Host Third Quarter 2024 Earnings Call

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

Oct 17, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups

alexpitti
alexpitti Jun. 1 at 1:49 AM
$DCTH replimune reported their data on rp2 which is their lesser known drug, but matters for us since it treats mUM among other things. they reported a pooled ORR of 33.3%. they had already reported 29.4% ORR in 5 of 17 patients. it looks to me like they added a few patients and maybe it went to 7 of 21 patients. they didn't say the exact number, but it's 1/3 obviously. this supports their goal of completing their trial, but not much else. i don't think delcath stock will react to this monday
0 · Reply
pufferfishcapital
pufferfishcapital May. 31 at 6:48 PM
$DCTH Breast trial has Cleveland Clinic, Moffitt, Ohio State, UT Southwestern, and IEO Milan. mCRC has City of Hope, Utah, Moffitt, Ochsner, UCLA, Kansas. There may be other intl sites not sure. Commercial requires a specific set of steps as prescribed in the FDA label i.e. proctoring, etc. A trial is less restrictive because the trial is done under a IND application. Ochsner has been listed in the HEPZATO referral site for quite a while and I am sure will eventually offer the procedure commercially, but I have no idea why it hasn't happened yet
0 · Reply
Jfree1121
Jfree1121 May. 30 at 11:27 AM
$DCTH if you spend a little time using any sort of AI platform, you can quickly find about 32 active centers. Throughout the country. And those are just ones that are publicly disclosed. There's probably at least half a dozen if not a dozen more that are currently leaning into it, but haven't publicly shared. Again, zoom out, the company continues to improve its financial standing and technology adoption quarter over quarter. I've been wrong about a number of stocks before, but this one I'm extremely bullish on 
1 · Reply
Value1008
Value1008 May. 30 at 12:00 AM
$DCTH - in some prior threads, Alex has mentioned the biotech (biomedical device) etf IHI as a sector comparison. IHI holds shares of large cap stocks, so doesn't currently hold any DCTH shares. But the overall sector sentiment would certainly seem to be influenced by IHI's performance. I queried Google AI on why the biomed device sector is so weak. Here was the reply: Stock values in the biomedical device (medtech) sector are being weighed down by a combination of high-valuation hangovers, supply-chain tariff pressures, and emerging fears that weight-loss drugs will reduce the long-term need for chronic disease interventions.The sector is facing several primary headwinds: The "GLP-1" Threat: The massive popularity of weight-loss drugs (like Wegovy and Zepbound) has sparked investor fear that a thinner, healthier population will require fewer cardiovascular interventions, joint replacements, and sleep apnea devices. [Continued...]
2 · Reply
Jfree1121
Jfree1121 May. 29 at 11:51 PM
$DCTH this is a long hold and will run. I know several docotors that rave about this tech and its results. Give it time people. Learn about the tech - this is a long term hold. If you're looking at it daily - just sell and move on or stfu.
1 · Reply
mar99
mar99 May. 29 at 8:04 PM
$DCTH Our typical end of day walk down. Another day of record highs in the indexes. Another day of garbage action in this dreadfully poor stock to be holding.
1 · Reply
alexpitti
alexpitti May. 29 at 6:29 PM
Someone fat fingered $DCTH no this is NOT an ai stock. Go back to your usual selling
0 · Reply
boohoooomillenials
boohoooomillenials May. 29 at 4:17 PM
$DCTH in at 10.74 with a 30k starter. Looking for 60-80% return
0 · Reply
mar99
mar99 May. 29 at 2:42 PM
$DCTH I guess today they aren’t bothering to run the stock up before the take down and figured it’s easier to just take it down. Tough place to be in this bull market. Hard to see any catalyst coming any time soon to change the story here with the stock price. S&P can go over 8,000 and we will still be struggling to see 11.
0 · Reply
alexpitti
alexpitti May. 29 at 1:30 PM
the fda is reviewing RP1 again quickly. seems like an approval is likely in the next 6 months. that will give replimune the money to keep funding the RP2 trial which competes with delcath. i think most of the enrollment will be done by year end. but an approval is still a few years away $DCTH
0 · Reply
GioW
GioW May. 28 at 8:24 PM
$DCTH nothing at ASCO of any interest apart from the fact that Delcath has a stand/booth this year. Maybe this could increase visibility of Hepzato.
1 · Reply
Playthegame06
Playthegame06 May. 28 at 8:24 PM
$DCTH Play the game people!!!!
0 · Reply
mar99
mar99 May. 28 at 8:07 PM
$DCTH So WTF? Same garbage different day with the same old pattern. Up 36 cents then the daily take down to close barely up 4 cents. Continuing to hold this stock thru this bull market as the market marches endlessly higher seems to be a seriously bad strategy. Time to trade this BS manipulation with a portion of my shares. I think I’ll take a few thousand shares and sell on the intraday run ups then buy back on the expected drop.
0 · Reply
alexpitti
alexpitti May. 28 at 8:04 PM
stock market is rigged. if you want the price to make sense, go look at the casino, not $DCTH
1 · Reply
actuallysam
actuallysam May. 28 at 3:29 PM
$DCTH It will be end of June for 2nd qtr and that is a long time given the crazy macro environment.
1 · Reply
brunoq14
brunoq14 May. 28 at 8:51 AM
$DCTH Is DCTH sharing anything at ASCO that might move the stock?
0 · Reply
Playthegame06
Playthegame06 May. 27 at 7:44 PM
$DCTH Huge HEADFAKE!!!
1 · Reply
alexpitti
alexpitti May. 27 at 7:28 PM
$DCTH we getting the ole smackdown get up smackdown more
0 · Reply
mar99
mar99 May. 27 at 7:17 PM
$DCTH And there we are in the red after being up 53 cents. Man this stock really does suck. The company is good but the stock really sucks.
0 · Reply
mar99
mar99 May. 27 at 6:48 PM
$DCTH This stock is so frustrating/annoying. Up to 11.36 this morning and already back below 11. Maybe they’ll even close us red after being up 50 cents. Yesterday up 23 cents before taking us down and closing down 19 cents. Prior day up 24 cents before selling and closing us down 43 cents. Crazy and frustrating.
1 · Reply
alexpitti
alexpitti May. 27 at 1:38 AM
med tech is historically cheap $SI $STXS $PROF $DCTH
0 · Reply
focafoca99
focafoca99 May. 26 at 8:32 PM
$DCTH launched two ASCO 2026 investigator‑initiated abstracts on HEPZATO trials in metastatic melanoma. https://www.rapidticker.com/news/dcth-delcath-systems-announces-two-asco-2fb9aa
1 · Reply